Teva and Ivax Bet on French Generics
Although generics still account for a paltry percentage of prescription drug usage in France, Ivax and Teva reckon the market is set to grow. Last April Ivax acquired all the products within Merck Sharpe & Dohme; just days later, Teva bought Bayer's French generics business. Teva and Ivax clearly hope that France-the world's fourth largest drug market-will follow its neighbors Germany and the UK, where generics represent a far greater proportion of the total pharmaceutical market.
You may also be interested in...
Patent expiries and cost-conscious governments are driving generics usage globally, but the highest growth is in Europe's southern markets-particularly France, Italy and Spain, where generics are in their infancy.
To Israel Makov, president and CEO of Teva, pressures on governments to cut the cost of medication mean the European generics market will soon be as big as the US market.
Buying Sobel Holdings makes Croatia's Pliva one of the first eastern European companies to buy into the US market. It's doing so cleverly, leveraging future revenues from its biggest product, azithromycin, to fund the deal, and executing it through a tax-efficient Hungarian subsidiary.